Abbott Laboratories Corporation

Other

Karin M Ostrom

James N Chmura

Louis I Ndife

Terrence B Mazer

Paul W Johns

Andre Daab-Krzykowski

Paul S Anloague

John D Suh

Fu-i Mei

Diane M Garcia

Milo Duane Hilty

Margaret Ione Dohnalek

Merlin D Breen

Kent Lee Cipollo

John D Benson

William T Malone

Helen R Churella

Michael J Neylan

David F Berk

Todd A Huston

Kent L Cipollo

Disclosed are calcium fortified, soy-based, infant nutritional formulas, including powder, liquid, or concentrate embodiments comprising per 100 kcal of formula (A) lipid, preferably up to about 8.0 g, (B) carbohydrate, preferably from about 8.0 g to about 16.0 g, (C) phytase-treated soy protein, preferably up to about 3.5 g and (D) calcium, preferably up to about 90 mg of calcium; wherein the nutritional formula is an infant formula having a calcium to lipid weight ratio of from about 0.002 to about 0.020, and wherein the formula contains not more than about 8.4 mg phytic acid per 100 kcal of formula. It has been found that these calcium-fortified, phytase-treated, soy-based, nutritional formulas provide for softer stools in infant populations, especially as compared to infants fed with other soy-based formulas including commercial soy formulas as well as soy based formulas derived from dephytinization methods other than phytase treatment, e.g., ion exchange.

Calcium fortified, soy based, infant nutritional formulas

The present invention relates generally to a method of producing plant proteins for use in nutritional products that have reduced levels of phytoestrogens, manganese or nucleotides. More specifically, this invention is directed to a method of using ion exchange technology to remove phytoestrogens, manganese or nucleotides from plant proteins. This invention is also directed to the plant protein product resulting from the inventive process and to nutritional products that use the plant protein product as a source of amino nitrogen.

Plant protein for nutritional products and method of making same

The use of fiber to control infantile colic and diarrhea and adult constipation and diarrhea is well accepted. This invention is specifically directed to liquid nutritional formulas which contain hydrolyzed protein and/or amino acids and dietary fiber. This invention overcomes the problems of product physical stability and high viscosities through the use of soluble/non-fermentable fibers in combination with a blend of insoluble/non-fermentable and soluble/fermentable fibers. The invention is also directed to the use of physiologically effective levels of fibers in nutritional products that use hydrolyzed protein and/or free amino acids for the source of amino nitrogen to treat colic, diarrhea, short gut syndrome and other gastrointestinal maladies.

Nuritional formula containing hydrolyzed protein and a fiber blend

A method is provided for reducing the incidence of otitis media in infants and young children by enterally administering indigestible fructooligosaccharides. More specifically, the present invention relates to a method for reducing the incidence of otitis media comprising administering to humans an indigestible fructooligosaccharide selected from the group consisting of 1-kestose, nystose and 1-.sup.F -B-fructofuranosyl nystose . The indigestible fructooligosaccharides can be produced through enzymatic synthesis, chemical techniques or isolated from plant materials and are administered in the form of a nutritional product, candy, tablets, chewing gums, lozenges, milk products, yogurts and the like. In a preferred embodiment of this invention, the fructooligosaccharides have a DP of 2 to 20 and still more preferably are the fructooligosaccharides FG.sub.2, GF.sub.3, and GF.sub.4.

Use of indigestible oligosaccharides to reduce the incidence of otitis

A method is provided for reducing the duration of diarrhea and recurrent episodes of diarrhea in humans by enterally administering indigestible oligosaccharides prophylactically. More specifically, the present invention relates to a method using indigestible oligosaccharides or fructooligosaccharides (FOS) to reduce the duration and recurrence of diarrhea in a human wherein between 0.5 grams and 5 grams of at least one FOS selected from the group consisting of 1-kestose, nystose, and 1.sup.F -.beta.-fructofuranosyl nystose is administered to said human per day. The indigestible oligosaccharides can be produced through enzymatic synthesis, chemical techniques or isolated from plant materials and are administered in the form of a nutritional product, candy, tablets, chewing gum, lozenges, milk, yogurts, fermented products and the like.

Use of indigestible oligosaccharides to prevent gastrointestinal

A hypercaloric formula providing nutritional support for human infants having chronic lung disease, said formula having a caloric density of at least 800 kcalories per liter of formula and wherein not less than 56% of the total calories in said formula is derived from fat; not more than 15% of total calories is derived from a high quality protein source; and from about 20-27% of total calories is from a carbohydrate source; said formula having a calcium to phosphorous ratio in the range of 1.4 to 2.2, and having an m-inositol concentration of at least 50 milligrams per liter of formula.

Nutritional product for human infants having chronic lung disease

Growing community of inventors

Reynoldsburg, OH, United States of America

Karin M Ostrom